Prix
GRAPH PAR
Questions fréquentes
Quelle est la capitalisation boursière de Valneva ?
Quel est le bénéfice par action (BPA) de Valneva ?
Quelles sont les évaluations des analystes et le prix cible de l'action Valneva ?
Quel est le chiffre d'affaires de Valneva sur les douze derniers mois ?
Quel est le flux de trésorerie disponible de Valneva ?
Combien d'employés compte Valneva, et à quel secteur d'activité appartient-elle ?
Quel est le flottant des actions de Valneva ?
Finances
- Capitalisation boursière
- 325,97 M $US
- BPA (TTM)
- -0,0458 $US
- Free Float
- 135,91 M
- Recettes (TTM)
- 165,39 M $US
- Cash-flow disponible (TTM)
- -182,86 M $US
Cotation
- 1D span
- 1,996 $US2,421 $US
- 52W span
- 1,812 $US5,472 $US
Notes des analystes
L'objectif de prix est de 8,081 $US et l'action est analysée par 10 analystes.
Acheter
9
Hold
1
Vendre
0
Informations
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.
- Salariés
- 676
- Industries
- Biotechnology
- Secteur
- Soins de santé
Identifiant
- ISIN
- FR0004056851
- Ticker primaire
- VLA